Biological responsiveness to first injections of interferon-beta in patients with multiple sclerosis

[1]  A. Bertolotto,et al.  Cotugno and cerebrospinal fluid , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[2]  A. Bertolotto,et al.  Neutralizing antibodies reduce the efficacy of βIFN during treatment of multiple sclerosis , 2004, Neurology.

[3]  M. Calabrese,et al.  The clinical impact of interferon beta antibodies in relapsing-remitting MS , 2004, Journal of Neurology.

[4]  L. Kappos,et al.  Neutralizing antibodies against IFN-β in multiple sclerosis: antagonization of IFN-β mediated suppression of MMPs , 2004 .

[5]  P. Sørensen,et al.  Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis , 2003, The Lancet.

[6]  R. Lindberg,et al.  Persistent neutralizing antibodies abolish the interferon β bioavailability in MS patients , 2003, Neurology.

[7]  L. Kappos,et al.  A randomized, double-blind, dose-comparison study of weekly interferon β-1a in relapsing MS , 2002, Neurology.

[8]  G. Kochs,et al.  Interferon‐Induced Mx Proteins: Dynamin‐Like GTPases with Antiviral Activity , 2002, Traffic.

[9]  J. Ilonen,et al.  Neutralizing antibodies reduce MxA protein induction in interferon- beta-1a-treated MS patients , 2002, Neurology.

[10]  C. Bancone,et al.  Evaluation of IFNα bioavailability by MxA mRNA in HCV patients , 2002 .

[11]  A. Castelló,et al.  Evaluation of bioavailability of three types of IFNbeta in multiple sclerosis patients by a new quantitative-competitive-PCR method for MxA quantification. , 2001, Journal of immunological methods.

[12]  A. Compston,et al.  Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis , 2001, Annals of neurology.

[13]  Richard A. C. Hughes,et al.  PRISMS-4: Long-term efficacy of interferon-&bgr;-1a in relapsing MS , 2001, Neurology.

[14]  D. Bever,et al.  PRISMS-4: Long-term efficacy of interferon-β-1a in relapsing MS , 2001, Neurology.

[15]  M. Reindl,et al.  A comparative study of the relative bioavailability of different interferon beta preparations , 2000, Neurology.

[16]  F. Heidenreich,et al.  Mx proteins in blood leukocytes for monitoring interferon beta-1b therapy in patients with MS , 2000, Neurology.

[17]  F. Spertini,et al.  Influence of interferon β-1a dose frequency on PBMC cytokine secretion and biological effect markers , 1999, Journal of Neuroimmunology.

[18]  M. Reindl,et al.  Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies , 1999, Neurology.

[19]  G. Williams,et al.  Comparative study of the pharmacodynamic and pharmacologic effects of Betaseron and AVONEX. , 1998, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[20]  R. Rudick,et al.  In vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis , 1998, Neurology.

[21]  Adrian Whitty,et al.  Structural and Functional Differences Between Glycosylated and Non-glycosylated Forms of Human Interferon-β (IFN-β) , 1998, Pharmaceutical Research.

[22]  R. Priore,et al.  Mechanism(S) of interferon inhibitory activity in blood from patients with AIDS and patients with lupus erythematosus with vasculitis. , 1997, Research communications in molecular pathology and pharmacology.

[23]  L. Wilkins.  Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b , 1996, Neurology.

[24]  Bruce Thompson,et al.  Advances in Social Science Methodology , 1994 .

[25]  Victoria P. Evans,et al.  Strategies for Detecting Outliers in Regression Analysis: An Introductory Primer. , 1999 .